Clozapine oral formulations - Jazz Pharmaceuticals

Drug Profile

Clozapine oral formulations - Jazz Pharmaceuticals

Alternative Names: clozapine ODT; clozapine once-daily; Clozapine QD; FazaClo HD; FazaClo LD; FazaClo ODT; Versacloz

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Alamo Pharmaceuticals; Alkermes plc; Douglas Pharmaceuticals
  • Developer Azur Pharma; Jazz Pharmaceuticals plc
  • Class Antipsychotics; Dibenzazepines
  • Mechanism of Action Dopamine D2 receptor antagonists; GABA receptor antagonists; Muscarinic receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 11 Feb 2014 Launched for Schizophrenia (treatment-resistant) in USA (PO, Suspension)
  • 30 May 2013 Biomarkers information updated
  • 20 Mar 2013 Clozapine controlled release is still in development for Schizoprenia in Ireland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top